{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK2118436+150mg", "query": { "intervention": "GSK2118436 150mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK2118436+150mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T20:09:09.334Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01954043", "title": "A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Dabrafenib 150 mg twice a day (BID)", "type": "DRUG" }, { "name": "Rabeprazole 40 mg once daily (OD)", "type": "DRUG" }, { "name": "Rifampin 600 mg OD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2013-12-20", "completion_date": "2016-02-29", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 3, "location_summary": "Goodyear, Arizona • Dallas, Texas • Tacoma, Washington", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Dallas", "state": "Texas" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954043" }, { "nct_id": "NCT03088176", "title": "Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "BRAF Gene Mutation" ], "interventions": [ { "name": "Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil", "type": "DRUG" }, { "name": "Talimogene Laherparep 100 Mil Pfu/Ml 1Ml", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2017-06-25", "completion_date": "2021-06-30", "has_results": false, "last_update_posted_date": "2020-10-12", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 1, "location_summary": "Germantown, Tennessee", "locations": [ { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03088176" }, { "nct_id": "NCT03455764", "title": "MCS110 With BRAF/MEK Inhibition in Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "MCS110", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-09-10", "completion_date": "2023-09-05", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03455764" }, { "nct_id": "NCT01336634", "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2011-08-05", "completion_date": "2021-01-07", "has_results": true, "last_update_posted_date": "2022-04-04", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 15, "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01336634" }, { "nct_id": "NCT01534897", "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Papillary Thyroid Carcinoma" ], "interventions": [ { "name": "GSK2118436", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-07", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534897" }, { "nct_id": "NCT04903119", "title": "Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "BRAF Gene Mutation" ], "interventions": [ { "name": "Nilotinib 100mg", "type": "DRUG" }, { "name": "Nilotinib 200mg", "type": "DRUG" }, { "name": "Nilotinib 300mg", "type": "DRUG" }, { "name": "Nilotinib 400mg", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rina Plattner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-06-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Lexington, Kentucky • Easton, Pennsylvania + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Easton", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04903119" }, { "nct_id": "NCT02281760", "title": "Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRAF V600E Mutation" ], "interventions": [ { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 9, "start_date": "2014-11-01", "completion_date": "2018-08-29", "has_results": true, "last_update_posted_date": "2021-08-31", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02281760" }, { "nct_id": "NCT01340846", "title": "A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Warfarin", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Gemfibrozil", "type": "DRUG" }, { "name": "GSK2118436 150mg", "type": "DRUG" }, { "name": "GSK2118436 75mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2012-09-03", "completion_date": "2012-11-14", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Sarasota, Florida • Detroit, Michigan + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01340846" }, { "nct_id": "NCT05585320", "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Pancreatic Adenocarcinoma", "Malignant Melanoma (Cutaneous)", "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "IMM-1-104 Monotherapy (Treatment Group A)", "type": "DRUG" }, { "name": "IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)", "type": "DRUG" }, { "name": "IMM-1-104 + modified FOLFIRINOX (Treatment Group C)", "type": "DRUG" }, { "name": "IMM-1-104 + dabrafenib (Treatment Group D)", "type": "DRUG" }, { "name": "IMM-1-104 + pembrolizumab (Treatment Group E)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immuneering Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 209, "start_date": "2022-10-31", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05585320" }, { "nct_id": "NCT04557956", "title": "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Tazemetostat Hydrobromide", "type": "DRUG" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-08-19", "completion_date": "2027-03-11", "has_results": true, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-20T20:09:09.334Z", "location_count": 17, "location_summary": "Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more", "locations": [ { "city": "Aventura", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04557956" } ] }